Supernus Pharmaceuticals (SUPN) Cash from Financing Activities (2011 - 2026)

Supernus Pharmaceuticals has reported Cash from Financing Activities for 16 years, with the latest figure at -$7.2 million in Q2 2026.

• Cash from Financing Activities for Q2 2026 came in at -$7.2 million, down 870.05% year-over-year; the trailing twelve-month figure through Jun 2026 was $31.5 million (up 374.02% YoY), and the FY2025 annual result was $9.1 million, down 25.12% from the prior year.
• Cash from Financing Activities slipped to -$7.2 million in Q2 2026, from $9.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $80.2 million in Q1 2023 and troughed at -$478.9 million in Q2 2023.
• A 5-year average of -$21.4 million and a median of $2.0 million in 2022 frame the typical range for Cash from Financing Activities.
• The widest annual swing landed in 2023, when Cash from Financing Activities slumped 21169.78%; it then surged 1436.96% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $2.8 million in 2022, then tumbled by 61.4% to $1.1 million in 2023, then soared by 439.38% to $5.9 million in 2024, then soared by 44.75% to $8.5 million in 2025, then tumbled by 184.45% to -$7.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$7.2 million in Q2 2026, $9.1 million in Q1 2026, and $8.5 million in Q4 2025.